Tarek S. Sewedy-El
Alexandria, ALX, Egypt
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Precision tumor targeting: gamma-irradiated ellagic acid therapy for ferroptosis and necroptosis modulation via GPX4/ALOX/RIPK/MLKL pathway inhibition.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: July 08, 2025
USP6NL knockdown suppresses colorectal cancer progression by inducing CASP9-Mediated apoptosis and disrupting FOXC2/SNAI1-Driven EMT and angiogenesis.
Journal: Functional & integrative genomics
Published: March 27, 2025
PFDN1 silencing disrupts critical cancer pathways in triple-negative breast cancer: investigating migration, cell cycle, and apoptosis as a new target therapy.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: January 11, 2025
Gold nanoparticles mediate suppression of angiogenesis and breast cancer growth via MMP-9/NF-κB/mTOR and PD-L1/PD-1 signaling: integrative in vitro validation and network pharmacology insights.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: September 18, 2024
Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment.
Journal: Medical oncology (Northwood, London, England)
Published: January 07, 2024
Chitosan-loaded piperlongumine nanoparticles and kaempferol enhance the anti-cancer action of doxorubicin in targeting of Ehrlich solid adenocarcinoma: in vivo and in silico modeling study.
Journal: Medical oncology (Northwood, London, England)
Published: November 15, 2023
Ammonia scavenger and glutamine synthetase inhibitors cocktail in targeting mTOR/β-catenin and MMP-14 for nitrogen homeostasis and liver cancer.
Journal: Medical oncology (Northwood, London, England)
Published: October 08, 2023
Novel phloretin-based combinations targeting glucose metabolism in hepatocellular carcinoma through GLUT2/PEPCK axis of action: in silico molecular modelling and in vivo studies.
Journal: Medical oncology (Northwood, London, England)
Published: October 08, 2023
Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death.
Journal: BMC complementary medicine and therapies
Published: January 11, 2023
Thymoquinone, piperine, and sorafenib combinations attenuate liver and breast cancers progression: epigenetic and molecular docking approaches.
Journal: BMC complementary medicine and therapies
Published: August 23, 2022
Showing 1-10 of 10
Last Updated: 09/26/2026